Campus Chemical Instrument Center, Mass Spectrometry & Proteomics Facility, The Ohio State University, Columbus, USA ...
The 2021 approval by regulatory agencies of belimumab, a B lymphocyte stimulator (BLyS) inhibitor, and the 2022 approval of anifrolumab, a type I interferon inhibitor, has increased the therapeutic ...
That pathway involves a chain reaction of events from a lipid called sphingosine-1-phosphate (S1P), protein kinase M zeta ...
AbbVie’s off-patent TNF blocker is, however, now being succeeded by cheaper biosimilars, namely Boehringer Ingelheim’s ...
FTY720 is a structural analogue of sphingosine that, after conversion to the biologically active FTY720-phosphate molecule, binds with high affinity to sphingosine-1-phosphate receptors to act as ...
FTY720 (fingolimod) is a structural analogue of sphingosine, an endogenous lysophospholipid, which targets sphingosine-1-phosphate receptors after biotransformation to FTY720-phosphate.
To date, there is no pharmacological therapy available to prevent AVD progression. Because valve calcification is the hallmark of AVD and S1P (sphingosine-1-phosphate) plays an important role in ...
Many lipids are found in mitochondria including one called sphingosine, which is a common component of many other cell membranes too. Sphingosine can increase the concentration of calcium ions inside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback